It is well known that allosteric modulators of muscarinic acetylcholine receptors can both diminish and increase the affinity of receptors for their antagonists. We investigated whether the allosteric modulators can also increase the affinity of receptors for their agonists. Twelve agonists and five allosteric modulators were tested in experiments on membranes of CHO cells that had been stably transfected with genes for the M 1 -M 4 receptor subtypes. Allosterically induced changes in the affinities for agonists were computed from changes in the ability of a fixed concentration of each agonist to compete with [ 3 H]Nmethylscopolamine for the binding to the receptors in the absence and the presence of varying concentrations of allosteric modulators. The effects of allosteric modulators varied greatly depending on the agonists and the subtypes of receptors. The affinity for acetylcholine was augmented by (Ϫ)-eburnamonine on the M 2 and M 4 receptors and by brucine on the M 1 and M 3 receptors. Brucine also enhanced the affinities for carbachol, bethanechol, furmethide, methylfurmethide, pilocarpine, 3-(3-pentylthio-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine (pentylthio-TZTP), oxotremorine-M, and McN-A-343 on the M 1 , M 3 , and M 4 receptors, for pentylthio-TZTP on the M 2 receptors, and for arecoline on the M 3 receptors. (Ϫ)-Eburnamonine enhanced the affinities for carbachol, bethanechol, furmethide, methylfurmethide, pentylthio-TZTP, pilocarpine, oxotremorine and oxotremorine-M on the M 2 receptors and for pilocarpine on the M 4 receptors. Vincamine, strychnine, and alcuronium displayed fewer positive allosteric interactions with the agonists, but each allosteric modulator displayed positive cooperativity with at least one agonist on at least one muscarinic receptor subtype. The highest degrees of positive cooperativity were observed between (Ϫ)-eburnamonine and pilocarpine and (Ϫ)-eburnamonine and oxotremorine-M on the M 2 receptors (25-and 7-fold increases in affinity, respectively) and between brucine and pentylthio-TZTP on the M 2 and brucine and carbachol on the M 1 receptors (8-fold increases in affinity). The discovery that it is possible to increase the affinity of muscarinic receptors for their agonists by allosteric modulators offers a new way to subtype-specific pharmacological enhancement of transmission at cholinergic (muscarinic) synapses.
It has long been known that the affinity of muscarinic receptors for their agonists and antagonists can be diminished by compounds acting allosterically (for reviews, see Refs. 1-3). It was discovered, however, that the affinity of cardiac muscarinic receptors for the muscarinic antagonist NMS can be increased by the neuromuscular blocker alcuronium (4, 5) . Subsequently, it was shown that the positive allosteric action of alcuronium on the binding of NMS is specific for the M 2 and M 4 muscarinic receptor subtypes (Ref. 6 , but see Refs. 7 and 8 for conflicting data concerning the M 3 and M 4 subtypes) and that it also applies to the binding of atropine, N-methylpiperidinyl benzilate, and several other muscarinic antagonists (9, 10) . Other compounds exerting positive allosteric effects on the binding of muscarinic antagonists were discovered recently, such as strychnine (11, 12) , (Ϫ)-eburnamonine (13) , fangicholine and tetrandrine (7) , and 9-methoxy-␣-lapachone (8) . It is obvious that it is important to know whether the allosteric modulators are also able to increase the affinity of muscarinic receptors for their agonists.
We investigated the effects of alcuronium and four compounds with structural similarities to alcuronium (strychnine, brucine, vincamine, and (Ϫ)-eburnamonine) on the affinities of muscarinic receptors of the M 1 -M 4 subtypes for acetylcholine and 11 other agonists. We discovered that the affinities for the agonists can be allosterically enhanced by most of the compounds tested, although the direction of the allosteric interaction (positive or negative) and its extent vary depending on receptor subtype and the nature of the agonist and allosteric modulator. To measure the affinities of receptors for the unlabeled agonists tested, we used a proce- dure devised by Proöka (10) 1 in which the allosterically induced changes in the affinity for the agonist are reflected by changes in the binding of a labeled classic antagonist ([ 3 H]NMS), which can be easily determined by the filtration method.
Materials and Methods

Reagents. [
3 H]NMS (80 Ci/mmol) was from DuPont-New England Nuclear (Dreieich, Germany). Arecaidine propargyl ester was from Cookson Chemicals (Southampton, UK). Acetylcholine iodide, arecoline, bethanechol, brucine, carbachol, (Ϫ)-eburnamonine, furmethide, methylfurmethide, oxotremorine, pilocarpine, strychnine, and vincamine were from Sigma Chemical (St. Louis, MO). McN-A-343 and oxotremorine-M were from Research Biochemicals (Natick, MA). Alcuronium was kindly provided by Hoffmann-La Roche (Basel, Switzerland), and pentylthio-TZTP was provided by Dr. P. Sauerberg (Copenhagen, Denmark). Pentylthio-TZTP is a thio analogue of the M 1 -selective muscarinic agonist xanomeline (14) (15) (16) .
Cells and cell membranes. Experiments were performed on membranes of CHO cell lines stably transfected with human genes for individual M 1 -M 4 subtypes of muscarinic receptors (17) . Cells were grown as described (6) in plastic dishes without coating in Dulbecco's modified Eagle's medium with 10% fetal calf serum and 0.005% geneticin. Seven days after subculturing, they were released by mild trypsinization, suspended in Dulbecco's modified Eagle's medium, and centrifuged for 3 min at 300 ϫ g. The sedimented cells were resuspended in homogenization medium composed of 136 mM NaCl, 5 mM KCl, 1 mM MgSO 4 , 1 mM Na-phosphate buffer, pH 7.4, and 10 mM Na-HEPES buffer, pH 7.4. They were washed twice through centrifugation (3 min at 300 ϫ g) and resuspension in fresh homogenization medium and then homogenized with an Ultra-Turrax homogenizer (Janke and Kunkel, Staufen, Germany). The homogenate was centrifuged for 10 min at 600 ϫ g, and the sediment was resuspended and recentrifuged. The supernatants from this and the previous centrifugation (containing the cell membranes) were combined, and their concentration was adjusted to correspond to 10 million cells of the starting suspension/1 ml. Then, they were kept frozen at Ϫ20°. On the day of the experiment, they were thawed and centrifuged for 15 min at 60,000 ϫ g; the sediment was washed twice through resuspension in the homogenization medium and recentrifugation.
Radioligand binding experiments. Radioligand binding and its changes in the presence of competitive and allosteric ligands were examined essentially as previously described (6, (18) (19) (20) . Membranes corresponding to 600,000 cells were incubated at 25°in a final volume of 0.8 ml for the time periods indicated below. The composition of the incubation medium corresponded with that of the homogenization medium, supplemented with 0.5 mM GTP in all binding experiments and with the ligands as indicated; GTP was included to induce the dissociation of G proteins from receptors. The incubation was terminated by filtration on Whatman GF/C glass-fiber filters in a Brandel cell harvester. (21)], were computed by nonlinear regression as previously described (6, 18, 19) . Allosteric interaction between the binding of the allosteric ligands (A) and the unlabeled agonists (L) was evaluated from changes in the binding of [ 3 H]NMS occurring in the presence of a fixed concentration of the agonist and of increasing concentrations of the allosteric ligand; it was characterized by the cooperativity coefficient ␤. The cooperativity coefficient ␤ is analogous to Ehlert's (21) coefficient ␣ and corresponds to the ratio of the K d value for the binding of an agonist to receptors occupied by the allosteric ligand and the K d value for the binding of the same agonist to free receptors. Correspondingly, ␤ Ͻ 1 in the case of positive cooperativity and ␤ Ͼ 1 in the case of negative cooperativity between the allosteric ligand and the agonist. In the current study, we reserve the use of the coefficient ␣ for the description of the cooperativity between the allosteric agents and the radiolabeled marker substance [ 3 H]NMS. The value of ␤ was computed according to eq. 3 [modified from Proška (10) 2 ] and based on the principles elaborated by Ehlert (21) . In the equations that follow, 
and the ratio between the binding of 
Eq. 3 was fitted to data on [ 3 H]NMS binding in the presence of a fixed concentration of L and of increasing concentrations of the allosteric ligand, obtained in experiments described under category D. (K X was determined in experiments of type A, K L was determined in experiments of type B, and K A and ␣ were determined in experiments of type C; this way, ␤ was the single unknown parameter in eq. 3).
Eq. 3 was found to be unsuitable for the description of data obtained in experiments with alcuronium as the allosteric ligand and with three of the tested agonists (oxotremorine, oxotremorine-M, and McN-A-343) on three receptor subtypes. The obtained data could be described, however, with the assumption that the binding of these agonists to the orthosteric binding site sterically precludes the binding of alcuronium to the allosteric binding site, and vice versa. With this assumption, the receptors can exist only as free receptors (R) or as complexes RX, RL, AR, and ARX, and eq. 4 applies: Table 1 .
Results
Saturation
Binding competition between agonists and 
The differences (indicated by Ͼ) were statistically significant when evaluated by Student's t test. Systematic correlation between the affinity (K A ) for a certain receptor subtype and the direction of the allosteric effect (positive or negative) was not apparent. Table 4 .
It is apparent from the data shown in Table 4 that both positive and negative allosteric interactions occurred between the agonists and the modulators examined. The direction of the interactions and their extent varied depending on the agonist, modulator, and subtype of the receptor. Of the 12 . As an explanation, we considered the possibility that the binding of these three agonists to the orthosteric binding site and of alcuronium to the allosteric binding site is mutually exclusive, presumably for steric reasons. If this were so, the system at equilibrium should conform to eq. 4. Fig. 3 shows that there is indeed a good fit between the data measured in experiments and the curves obeying eq. 4. The sums of squares of differences were lower with eq. 4 than with eq. 3, but the difference was significant only at the M 2 receptor (F test).
Discussion
The main finding of the current study consists in the discovery of positive effects of allosteric modulators on the affinity of muscarinic receptors for muscarinic agonists, including acetylcholine. Only negative effects of allosteric modulators on the affinities of muscarinic receptors for agonists have been reported (22) (23) (24) (25) . The discovery is important Table 4. for several reasons: (a) It suggests that drugs may be developed with the potential for increasing the efficiency of cholinergic (muscarinic) synaptic transmission in a very physiological way, by enhancing the sensitivity of postsynaptic receptors toward their natural agonist. (b) It points to a new way to achieve subtype-and tissue-specific activation of muscarinic receptors. Although the subtype selectivity of most muscarinic agonists is low, suitable allosteric modulators should permit the selective enhancement of the effect of a nonselective muscarinic agonist on a single receptor subtype and suppression of it on the other receptor subtypes (e.g., (Ϫ)-eburnamonine-induced changes in the affinities for acetylcholine). (c) The enhancement of synaptic transmission by allosteric modulators is likely to be extremely safe and completely activity dependent. The effects of allosteric ligands have clear-cut inherent pharmacodynamic limits because they alter the K d values for agonists and antagonists within a defined range. This should help to avoid receptor overstimulation (by allosteric enhancers) and overinhibition (by allosteric inhibitors). It is also important that the allosteric enhancers will act only when the presynaptic nerve terminal is active and the neurotransmitter is released, because they must bind to receptors simultaneously with the neurotransmitter to have an effect (26, 27) . The question of whether allosteric enhancers will affect receptor desensitization requires specific investigation.
It seems unlikely that the five allosteric modulators we examined will be used as allosteric enhancers in medical practice, mainly because their affinities for receptors are low (K A ϭ 0.7 ϫ 10 Ϫ6 to 10 4 ϫ 10 Ϫ6 ; Table 3 ) and because some of them have additional undesirable effects. It is not difficult to imagine, however, that chemically related compounds with higher potency and allosteric efficacy and with no toxicity will be discovered, which will prove suitable for modulation of muscarinic receptor function in medical practice. It seems impossible to say at present which features of the modulator, receptor, and agonist determine the direction (positive or negative) of the cooperative interaction; we can only offer several comments relevant to this point:
Receptor subtype. Literature on the negative allosteric effects of neuromuscular blockers on muscarinic receptors (28) suggests that the M 2 receptor subtype is most prone to allosteric modulation. Observations that the allosteric enhancement of the binding of NMS by alcuronium (4, 5, 7, 8) and strychnine (11, 12) is strongest on the M 2 receptors and that alcuronium has the highest affinity for the M 2 receptors (6) led to anticipation that the positive allosteric effects on the binding of agonists would also mainly occur on the M 2 receptor subtype. The present data do not support such expectation. Allosteric enhancement of agonist binding could be revealed on all four receptor subtypes examined. The affinity for the physiological agonist acetylcholine was allosterically enhanced on the M 1 and M 3 subtypes by brucine and on the M 2 and M 4 subtypes by (Ϫ)-eburnamonine.
Affinity for the allosteric modulator. In the membranes of transfected CHO cells, the values of K d for the binding of alcuronium to muscarinic receptor subtypes were 9.33, 0.62, 1.56, 1.31, and 22.0 M on the M 1 , M 2 , M 3 , M 4 and M 5 , receptor subtypes, respectively (6) , and the cooperativity between alcuronium and NMS was positive on the M 2 and M 4 and negative on the M 1 , M 3 , and M 5 subtypes. These data suggested that the effects of an allosteric ligand might be ]NMS was observed on the two receptor subtypes for which the affinity of (Ϫ)-eburnamonine was the lowest. No generally valid correlation is evident between the rank orders of the affinities of allosteric modulators for receptors and the rank orders of the ␤ factors computed for their interactions with individual agonists. For example, brucine has a 100-fold higher affinity for the M 4 than for the M 3 subtype, but its cooperativity with most agonists is similar on both subtypes.
Affinity for the agonist. This factor is difficult to consider with the current data because the experiments were performed in the presence of 0.5 mM GTP, which eliminated the high affinity binding of agonists. Under these conditions, no consistent correlation is apparent between the K L values of agonists in Table 2 and the relevant cooperativity factors ␤ in Table 4 . For complete analysis, it will be necessary to explore the cooperativity between agonists and allosteric modulators under conditions in which the receptor/G protein coupling occurs in a normal way, but this will be demanding in view of the complexity of the system and of recent data indicating that the allosteric modulators themselves modify the receptor/G protein interactions (29) .
We do not know of any published data indicating that that the allosteric modulators potentiate the functional responses to muscarinic agonists. We hope, however, that our data on the positive allosteric effects on agonist binding, as summarized in Table 4 , will facilitate the discovery of positive modulations of functional responses to agonists.
As noted in Results, data on the binding of [ 3 H]NMS to the M 1 , M 2 , and M 4 receptor subtypes in the simultaneous presence of alcuronium and oxotremorine, oxotremorine-M, or McN-A-343 seemed incompatible with eq. 3 and thereby with the assumptions on which it had been derived. This problem did not arise when the three agonists were present simulta- neously with strychnine, brucine, vincamine, or (Ϫ)-eburnamonine. In attempts to explain this, we considered the possibility that alcuronium cannot bind to the allosteric site when the orthosteric site is occupied by oxotremorine, oxotremorine-M, or McN-A-343, and vice versa. If this were so, the binding of [ 3 H]NMS should correspond to eq. 4. We have found that the correspondence between the data and eq. 4 was indeed better than that between the data and eq. 3 (significantly better in the case of M 2 receptors), which supports the hypothesis but does not prove it. Experimental examination of this point will be facilitated when radiolabeled allosteric modulators become available.
In conclusion, we found that the affinity of muscarinic receptors for acetylcholine and pharmacological agonists may be increased by allosteric modulators and that the effect of the modulators is highly subtype selective. Using allosteric modulators, it may become possible to achieve subtype-selective stimulation of muscarinic receptors by acetylcholine and other subtype-nonselective agonists.
Note Added in Proof
While this article was in press, an article appeared that described positive allosteric effect of brucine and its two derivatives on the binding of acetylcholine to muscarinic receptors [Birdsall, N.J.M., T. 
